Summary & Overview
HCPCS Level II Q0520: Pharmacy Fee for Injectable HIV PrEP, 60-Day Supply
HCPCS Level II code Q0520 designates a pharmacy supplying fee for FDA-approved injectable HIV pre-exposure prophylaxis (PrEP), billed per 60-day supply. This code is used to capture the pharmacy service component when an injectable PrEP medication is dispensed, separating the drug administration and clinical services from the pharmacy dispensing fee. Nationally, accurate use of this HCPCS Level II code supports clear claims processing, benefit design, and monitoring of access to long-acting PrEP options.
Key payers addressed in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of the clinical context for injectable PrEP, billing and coding considerations tied to pharmacy supply fees, and what payers commonly recognize in coverage terms. The publication outlines benchmarks for claim lines tied to dispensing fees, summarizes potential billing scenarios where Q0520 is expected to appear, and highlights policy and coding guidance that affects claim adjudication and benefit administration.
This summary serves pharmacists, billing professionals, payer policy staff, and clinicians who manage PrEP programs by clarifying when Q0520 applies, how it relates to the service delivery setting, and what to expect in payer coverage conversations. Data not available in the input for taxonomy, diagnosis linkage, and related service lines is noted where relevant.
Billing Code Overview
HCPCS Level II code Q0520 describes a pharmacy supplying fee for HIV pre-exposure prophylaxis FDA-approved prescription injectable drug, per 60-days. This code covers the pharmacy service component associated with dispensing and supplying an FDA-approved injectable medication used for HIV pre-exposure prophylaxis (PrEP).
-
Service type: Pharmacy supplying fee for injectable PrEP medication, billed per 60-day supply
-
Typical site of service: Outpatient pharmacy setting or clinic-based pharmacy dispensing for outpatient use
Clinical & Coding Specifications
Clinical Context
A 28-year-old cisgender man with multiple male sexual partners presents to a community sexual health clinic seeking HIV prevention. He underwent initial screening: negative HIV antigen/antibody, normal renal function (eGFR >60 mL/min/1.73m2), and screening for hepatitis B and STIs. The clinician prescribes an FDA‑approved injectable HIV pre‑exposure prophylaxis agent with a 60‑day supply interval. The pharmacy bills the supplying fee for the injectable PrEP using Q0520 per 60 days. Typical workflow: evaluation and counseling by a prescribing clinician (primary care, infectious disease specialist, or sexual health clinician) → baseline labs and HIV test → prescription and coordination with the dispensing pharmacy → pharmacy documents medication administration or patient self‑administration training and submits Q0520 for the pharmacy supplying fee covering the 60‑day injectable dose. Follow‑up visits for HIV testing and renal monitoring are scheduled per clinical guidelines, and subsequent pharmacy claims use Q0520 at each 60‑day dispensing interval as applicable.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
22 | Increased procedural services | Use when additional work or complexity beyond usual is documented for pharmacy supply coordination (rare for this code). |